文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

难治性心脏骤停体外心肺复苏中Impella左心室卸载:系统评价与Meta分析

Left-Ventricular Unloading With Impella During Refractory Cardiac Arrest Treated With Extracorporeal Cardiopulmonary Resuscitation: A Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Med · 2024-01-05
一句话结论ECPR期间ECMELLA支持与住院死亡率降低(OR 0.53 [95%CI 0.30-0.91])和良好神经预后几率升高(OR 2.22 [95%CI 1.17-4.22])相关,但原文指出证据尚需进一步研究。

该系统评价与Meta分析纳入截至2023年7月的观察性研究,共13项研究记录、32家医院、1014例接受ECPR的成年难治性心脏骤停患者。762例(75.1%)接受VA-ECMO,252例(24.9%)接受ECMELLA。与VA-ECMO相比,ECMELLA组初始可电击心电图节律(58.6% vs. 49.3%)、急性心肌梗死(79.7% vs. 51.5%)和经皮冠状动脉介入治疗(79.0% vs. 47.5%)比例更高;VA-ECMO单独更常用于肺栓塞(9.5% vs. 0.7%)。ECMELLA与死亡率降低(OR 0.53 [95%CI 0.30-0.91])和良好神经预后几率升高(OR 2.22 [95%CI 1.17-4.22])相关,并发症率数值上增加但无统计学显著差异。作者结论认为ECPR期间ECMELLA可能改善生存和神经预后,但各机构适应证和频率差异很大,亟需进一步科学证据制定标准化指南。

要点

  • 在1014例ECPR成人难治性心脏骤停患者中,ECMELLA组(252例,24.9%)较VA-ECMO组(762例,75.1%)住院死亡率降低(OR 0.53 [95%CI 0.30-0.91])。
  • ECMELLA组良好神经预后几率高于VA-ECMO组(OR 2.22 [95%CI 1.17-4.22])。
  • ECMELLA组初始可电击心律(58.6% vs. 49.3%)、急性心肌梗死(79.7% vs. 51.5%)和PCI(79.0% vs. 47.5%)比例更高,VA-ECMO单独更常用于肺栓塞(9.5% vs. 0.7%)。
  • ECMELLA治疗并发症率数值上增加但无统计学显著差异;主要结果在多项敏感性分析中保持稳健。
  • 作者指出各机构ECMELLA适应证和频率差异很大,亟需进一步科学证据制定ECPR期间左心室卸载的标准化指南。

适用人群与场景

  • 成年难治性心脏骤停接受ECPR(VA-ECMO)的患者,来自13项观察性研究记录、32家医院,共1014例。
  • ECMELLA组252例(24.9%),VA-ECMO组762例(75.1%)。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,纳入截至2023年7月的观察性研究,共13项研究记录、32家医院、1014例ECPR患者;采用Mantel-Haenszel检验随机效应模型计算OR和95%CI。
  • 与VA-ECMO相比,ECMELLA组初始可电击心电图节律比例更高(58.6% vs. 49.3%)、急性心肌梗死比例更高(79.7% vs. 51.5%)、经皮冠状动脉介入治疗比例更高(79.0% vs. 47.5%)。
  • VA-ECMO单独更常用于肺栓塞(9.5% vs. 0.7%);两组年龄、院外心脏骤停比例和低流量时间相似。
  • ECMELLA支持与死亡率降低相关(OR 0.53 [95%CI 0.30-0.91]),与良好神经预后几率升高相关(OR 2.22 [95%CI 1.17-4.22])。
  • ECMELLA治疗并发症率数值上增加但无统计学显著差异;主要结果在多项敏感性分析中保持稳健。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入观察性研究。
  • 局限:原文指出各机构ECMELLA支持的适应证和频率差异很大;亟需进一步科学证据以制定ECPR期间左心室卸载的标准化指南。

对床旁实践的改变

  • 作者结论认为ECPR期间ECMELLA支持可能改善生存和神经预后,但原文同时指出各机构适应证和频率差异很大,亟需进一步科学证据制定标准化指南。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Extracorporeal cardiopulmonary resuscitation (ECPR) is the implementation of venoarterial extracorporeal membrane oxygenation (VA-ECMO) during refractory cardiac arrest. The role of left-ventricular (LV) unloading with Impella in addition to VA-ECMO ("ECMELLA") remains unclear during ECPR. This is the first systematic review and meta-analysis to characterize patients with ECPR receiving LV unloading and to compare in-hospital mortality between ECMELLA and VA-ECMO during ECPR.

DATA SOURCES: Medline, Cochrane Central Register of Controlled Trials, Embase, and abstract websites of the three largest cardiology societies (American Heart Association, American College of Cardiology, and European Society of Cardiology).

STUDY SELECTION: Observational studies with adult patients with refractory cardiac arrest receiving ECPR with ECMELLA or VA-ECMO until July 2023 according to the Preferred Reported Items for Systematic Reviews and Meta-Analysis checklist.

DATA EXTRACTION: Patient and treatment characteristics and in-hospital mortality from 13 study records at 32 hospitals with a total of 1014 ECPR patients. Odds ratios (ORs) and 95% CI were computed with the Mantel-Haenszel test using a random-effects model.

DATA SYNTHESIS: Seven hundred sixty-two patients (75.1%) received VA-ECMO and 252 (24.9%) ECMELLA. Compared with VA-ECMO, the ECMELLA group was comprised of more patients with initial shockable electrocardiogram rhythms (58.6% vs. 49.3%), acute myocardial infarctions (79.7% vs. 51.5%), and percutaneous coronary interventions (79.0% vs. 47.5%). VA-ECMO alone was more frequently used in pulmonary embolism (9.5% vs. 0.7%). Age, rate of out-of-hospital cardiac arrest, and low-flow times were similar between both groups. ECMELLA support was associated with reduced odds of mortality (OR, 0.53 [95% CI, 0.30-0.91]) and higher odds of good neurologic outcome (OR, 2.22 [95% CI, 1.17-4.22]) compared with VA-ECMO support alone. ECMELLA therapy was associated with numerically increased but not significantly higher complication rates. Primary results remained robust in multiple sensitivity analyses.

CONCLUSIONS: ECMELLA support was predominantly used in patients with acute myocardial infarction and VA-ECMO for pulmonary embolism. ECMELLA support during ECPR might be associated with improved survival and neurologic outcome despite higher complication rates. However, indications and frequency of ECMELLA support varied strongly between institutions. Further scientific evidence is urgently required to elaborate standardized guidelines for the use of LV unloading during ECPR.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Thevathasan T, Füreder L, Fechtner M, et al. Left-Ventricular Unloading With Impella During Refractory Cardiac Arrest Treated With Extracorporeal Cardiopulmonary Resuscitation: A Systematic Review and Meta-Analysis. Crit Care Med. 2024. PMID: 38180032. doi:10.1097/CCM.0000000000006157

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。